Stocks · News reference
Morgan Stanley reaffirmed its Underweight rating on Bristol Myers Squibb and reduced its price target from $41 to $40.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Viz.ai announced that two research abstracts evaluating its AI-powered electrocardiogram technology, developed in partnership with Bristol Myers Squibb, have been accepted for presentation at the Hypertrophic Cardiomyopathy Medical Society meeting.
Zenas BioPharma recognized $10 million in revenue during the third quarter of 2026 related to a development milestone achieved under its license and collaboration agreement with Bristol Myers Squibb.
Bristol Myers Squibb has selected Polaris Rx as a specialty pharmacy provider for ZENBEXUS™ (iberdomide), its recently FDA-approved therapy for multiple myeloma.
Bristol Myers Squibb Canada has launched "What Summer Leaves Behind," a public awareness campaign designed to help identify the warning signs of melanoma and other skin cancers.
Bristol Myers Squibb and partner SystImmune announced positive interim results from the Phase 3 PANKU-Breast01 study evaluating the bispecific antibody-drug conjugate izalontamab brengitecan (iza-bren).
Over 45 pharmaceutical companies are advancing 50+ pipeline drugs for sickle cell disease treatment. Key developments include Agios Pharmaceuticals' mitapivat receiving FDA Priority Review, Novo Nordisk's etavopivat meeting Phase III endpoints, and CorrectSequence Therapeutics' CS-206 showing sustained vaso-occlusive crisis-free results. The pipeline features diverse mechanisms including PK activators, gene therapies, and fetal hemoglobin stimulants, with approximately 5+ drugs in late-stage development.